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Abstract
The neuroepithelial stem cell protein, or Nestin, is a cytoskeletal intermediate filament initially characterized in neural stem 
cells. However, current extensive evidence obtained in in vivo models and humans shows presence of  Nestin+ cells with 
progenitor and/or regulatory functions in a number of additional tissues, remarkably bone marrow. This review presents the 
current knowledge on the role of Nestin in essential stem cell functions, including self-renewal/proliferation, differentiation 
and migration, in the context of the cytoskeleton. We further discuss the available in vivo models for the study of  Nestin+ 
cells and their progeny, their function and elusive nature in nervous system and bone marrow, and their potential mechanistic 
role and promising therapeutic value in preclinical models of disease. Future improved in vivo models and detection methods 
will allow to determine the true essence of  Nestin+ cells and confirm their potential application as therapeutic target in a 
range of diseases.
Keywords Nestin · Central and peripheral nervous systems · Hematopoietic stem cell niche · Neural stem and progenitor 
cells · Mesenchymal stromal cells · Mouse models · Neurodegenerative diseases · Hematological malignancies
Introduction
The neuroepithelial stem cell protein, more commonly 
known as Nestin, is a cytoskeletal protein classified as 
intermediate filament, initially described in neural stem 
cells (NSCs) of developing and adult brains [1, 2], and now 
known to be expressed in a variety of tissues and stem or 
progenitor cells, like pancreatic islets [3], skeletal muscle 
satellite cells [4], developing myotomes [5], testis [6], hair 
follicle [7], heart [8], and the non-hematopoietic fraction of 
the bone marrow [9–11]. Additionally, Nestin seems to play 
a role in pathogenesis and it is expressed in several types of 
malignancies, such as osteosarcoma, neuroblastoma, glioma, 
melanoma, pancreatic and prostate cancers as well as in 
tumor vasculature [12]. Further, Nestin is considered a bio-
marker of invasive phenotype, and is associated to infiltra-
tion in glioblastoma [13], angiogenesis in numerous malig-
nancies [14] and spreading of non-epithelial and epithelial 
tumors [15]. This review focuses on the role of Nestin in the 
context of the cytoskeleton, the available in vivo models for 
the study of  Nestin+ cells and their progeny, their function 
and nature in two major systems, neural and bone marrow, 
and their role and promising therapeutic value in preclinical 
models of disease of these two systems.
Nestin: the stem cell intermediate filament
Nestin is classified as type VI intermediate filament, and 
constitutes a major component of the cytoskeleton. In con-
trast to general cytoskeletal elements, intermediate filaments 
are expressed in a cell-type specific manner in a way that 
major differentiation steps are marked by transition from 
one intermediate filament type to another. The complex-
ity of intermediate filaments is remarkable, consisting of 
more than 50 distinct proteins able to form morphologically 
similar filaments in different cell subsets [16]. Polymerized 
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intermediate filaments assemble through a highly conserved 
domain, whereas end domains of variable size and chemis-
try provide them with a wide variety of unique binding and 
regulating characteristics (Fig. 1) [16].
To date, six different types of intermediate filaments have 
been described (Table 1) according to their gene structure 
and protein sequence homology throughout their rod, head 
and tail domains. They include types I/II keratins, selective 
of epithelia; five type III proteins widely expressed, includ-
ing vimentin expressed by mesenchymal cells; five type IV 
chains including neurofilaments and usually expressed only 
in neuronal tissues; several type V nuclear lamins expressed 
in many nucleated cells; and Nestin, a single type VI pro-
tein characteristic of a variety of stem cells, and NSCs in 
particular (Table 1). In terms of gene structure and protein 
sequence, the singularity of Nestin is unclear as it shows cer-
tain degree of similarity with type III and particularly type 
IV intermediate filaments [16]. Actually, it was proposed 
for reclassification as type IV intermediate filament based 
on its structure similar to neurofilaments [17]. However, due 
to differences in the α-helical region and its unique short 
N-terminus end and long C-terminus end (Fig. 1), it is still 
extensively considered as a separate entity [1, 16, 18]. In 
those classifications where Nestin is considered as a type 
IV intermediate filament, the type VI group includes two 
lens-specific proteins that bear little resemblance to other 
intermediate filaments and form beaded filaments: filensin 
and phakinin [19].
According to the Human Protein Atlas, Nestin is 
expressed in a variety of tissues including brain, bone 
marrow, immune system, muscle, lung, gastrointestinal 
tract, kidney and urinary bladder, adipose and soft tissues, 
female tissues and skin. Interestingly, mouse models have 
shown that enrichment of Nestin is evident and selective 
in several subsets of stem cells; yet it is unclear how Nes-
tin influences stemness.  Nestin+ cells from the adult brain 
are able to form neurospheres ex vivo and generate differ-
entiated cells of neuronal and astrocytic lineages, which 
downregulate Nestin expression during differentiation [2]. 
 Nestin+ cells from the adult bone marrow contain all the 
bone marrow colony forming unit fibroblastic activity and 
may be expanded as mesenspheres that self-renew in serial 
transplantations. Ex vivo, these cells can differentiate into 
osteoblastic, adipocytic and chondrocytic lineages, progeny 
that does not express Nestin [9]. Further, Nestin seems to 
be a marker of proliferation, given that most  Nestin+ cells 
are also positive for the proliferation marker Ki-67 and are 
labeled by 5-bromo-2-deoxyuridine (BrdU) incorporation 
reflecting a proliferative state [2, 20]. This stands in contrast 
with  Nestin+ periarteriolar cells from adult bone marrow 
that were found to be largely quiescent in vivo [21], diver-
gence indicative of the potential cell-type specific roles for 
Nestin. Thus, Nestin is related to essential stem cell func-
tions, including self-renewal/proliferation, differentiation 
and migration.
Self‑renewal/proliferation
The typical proliferative property of stem cells that ensures 
tissue homeostasis is asymmetric cell division, as it allows 
maintenance of the stem pool and generation of functional 
differentiated cells in parallel [22]. Asymmetric cell division 
leads to asymmetric inheritance of cellular components dur-
ing cell division, which determines distinct cell fate for each 
daughter cell [23]; one of them retains self-renewal capac-
ity and differentiation potential, whereas the other starts the 
differentiation path. This requires a series of profound mor-
phological changes, including cytoskeletal arrangements that 
induce and maintain cell polarity.
The spindle apparatus is the cytoskeletal structure that 
forms during cell division to separate sister chromatids 
between daughter cells, and it includes mainly microtubules 
and associated proteins, like kinesin and dynein. Spindle ori-
entation contributes to establishment of asymmetry in stem 
cell division and fate. For instance, it contributes to differ-
ential signaling environments in daughter cells [24]. In the 
developing cerebral cortex, horizontal divisions are mainly 
asymmetric and produce basal daughter cells that behave 
like young migratory neurons and apical daughter cells that 
remain within the proliferative zone, in contrast to vertical 
divisions that are preferentially symmetric and produce pre-
cursor cells. This was related to selective Notch1 inheritance 
by the basal neuron in horizontal divisions [25]. Further, 
Fig. 1  Nestin structure and assembly into intermediate filament. a 
Molecular structure of Nestin. Nestin shares a common structure with 
the other intermediate filaments that consists of a central α-helical 
rod domain (blue) of conserved size, flanked by a globular N-termi-
nus (‘head’, red) and C-terminus (‘tail’, green) domains. The central 
α-helical rod domain consists of three segments separated by two 
linkers, i.e., coil 1A, linker 1, coil 1B, linker 12 and coil 2, with 2A 
and 2B and stutter between them. b Particularities of Nestin mono-
mer. Nestin shows a short N-terminus (≈ 8 amino acids) and a long 
C-terminus (> 1400 amino acids) end, compared to other intermedi-
ate filaments like vimentin (≈ 100 and 400 amino acids, respectively). 
c Nestin forms heterodimers. N-terminus is required for intermedi-
ate filament assembly, and free C-terminus may interact with other 
cytoskeleton components. The short N-terminus disables Nestin to 
self-assemble into higher order structures, so Nestin needs other 
intermediate filaments to assemble, like vimentin. The central rod 
domain contains hydrophobic repeats (heptad repeats) that mediate 
dimerization allowing two α-helices to wrap around each other and 
become a ‘coiled coil’. Therefore, intermediate filament dimer rod 
central domain is known as central rod coiled domain. d Hypotheti-
cal intermediate filament assembly. Two dimers coil in antiparallel 
way in head-to-tail association to make a tetramer. Assembly takes 
place through rapid lateral aggregation of eight tetramers to form sub-
filaments, which assemble axially to form the intermediate filament 
(diameter ~ 10  nm). Numbers in N-termini and C-termini ends indi-
cate number of amino acid residues. N-ter N-terminus, C-ter C-ter-
minus
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spindle orientation defines nuclei position. In the early 
mouse embryo, as the 8-cell embryo progresses through the 
cell cycle, the nuclei of most cells move from apical to basal 
positions, in a microtubule- and kinesin-dependent man-
ner [26]. Asymmetric cell divisions occur when nuclei are 
located basally, whereas cells showing apical nuclei divide 
symmetrically [26].
Hence, microtubules are well-known players in nuclear 
positioning, but the role of actin has also been high-
lighted. In the C. elegans embryo, mutations and chemi-
cals affecting actin function disrupt partitioning-defective 
(Par) proteins asymmetry [27–29], which establish and 
maintain anterior–posterior polarity in the embryo [30]. 
Later, asymmetric inheritance of Par family proteins was 
demonstrated to contribute to the asymmetric outcome 
of neural glia divisions during development in mice [31, 
32]. Further, in certain cell types like astrocytes, the retro-
grade flow of actin attracts major intermediate filaments, 
including Nestin, vimentin and glial fibrillary acidic pro-
tein (Gfap), in front of the nucleus, and thereby transfers 
pushing force that conditions nuclear positioning [33]. 
Using a neuronal progenitor cell line, ST15A, Sahlgren 
and colleagues showed that Nestin reorganization during 
mitosis is coupled to an increase in Nestin phosphorylation 
that contributes to partial disassembly of Nestin filaments 
[34]. Nestin may play a role in the regulation of assem-
bly and disassembly of other intermediate filaments, like 
vimentin, during mitosis [35], and was proposed as media-
tor of the interaction between intermediate filaments with 
microtubules and/or microfilaments [17].
Table 1  Intermediate filament types, characteristic cell subsets and main function
K keratin, CNS central nervous system, PNS peripheral nervous system, NF neurofilament
IF type Protein No genes Size (kDa) Cell subsets Function References
I Keratins (acidic) > 25 40–60 K9–K20 and K23: soft epithe-
lia; K31–K38: hard epithelia
Structural integrity, mechani-
cal resistance, adhesion, sig-
nal transduction, inflamma-
tion, proliferation, apoptosis, 
motility
[116–119]
II Keratins (basic) > 24 50–70 K1–K8: soft epithelia; K81–
K86, hard epithelia; K71–
K74: inner root sheath
III Vimentin 1 53 Mesenchymal cells, develop-
ing neurons, astrocytes, 
endothelial cells, leukocytes
Structural maintenance, cell 
shape, motility, focal adhe-
sion
[74]
Glial fibrillary acidic protein 1 51 Neural stem cells, radial glia-
like precursors, astrocytes, 
regenerative glia, mature glia 
in CNS and PNS
Structural maintenance, cell 
shape, motility
[2, 71–74, 120]
Desmin 1 53 Satellite stem cells, striated 
muscle, replicating myo-
blasts, fibroblastic reticular 
cells of lymphoid organs
Contraction [121, 122]
Peripherin 1 58 Mature neurons in PNS Neurite elongation [123]
Syncoilin 1 64 Skeletal and cardiac muscle, 
nervous system
Structural maintenance [124]
IV NF light 1 68 Maturing neurons in CNS, 






NF medium 1 160
NF heavy 1 240
α-Internexin 1 66 Postnatal, maturing and mature 
neurons
[126]
Synemin 1 230 Mature neurons in PNS, glia, 
skeletal and cardiac muscle
Structural maintenance [74]
V Lamin A/C 1 60–75 Nucleus, cell specific Nuclear shape, chromatin 





VI Nestin 1 240 Neural stem and progeni-
tor cells, neurogenic cells, 
radial glia-like precursors, 
regenerative glia, mesenchy-
mal stromal cells, subsets of 
endothelial cells, Schwann 




[2, 9, 10, 20, 
36, 47, 48, 
50]
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However, in Nestin knockout mice, the dramatic reduction 
in NSC survival and self-renewal occurs with no defects in 
microfilaments, microtubules or vimentin-based intermedi-
ate filaments, or changes in proliferation [36]. Surprisingly, 
a second Nestin−/− mouse model was generated that showed 
grossly normal development of the central nervous system 
[37], although this work did not examine functional changes 
in NSCs. Unknown technical issues related to genetic engi-
neering may underlie these unexpected differences. In both 
NSCs and ST15A cells, Nestin may protect from apoptosis 
by an independent mechanism that consists of binding to 
cyclin-dependent kinase 5; thereby inhibiting its proapop-
totic function [36, 38]. Others have reported that Nestin 
is essential for proliferation of embryonic cortical neural 
progenitor cells. Small interference RNAs against Nestin 
were used to downregulate Nestin during rat brain develop-
ment, resulting in G1 cell cycle arrest and reduced numbers 
of new neurons in vivo. Further, Nestin downregulation in 
cultured cortical neural progenitor cells inhibits their col-
ony-formation capacity and causes a marked suppression 
in the phosphoinositide 3-kinase (PI3K) pathway under 
stimulation with growth factors. These effects are inde-
pendent of vimentin, and can be rescued by up-regulation 
of PI3K activity [39]. Using the opposite strategy, Liu and 
colleagues showed that Nestin overexpression in vivo, in 
mouse embryos expressing a human Nestin cDNA transgene 
under the control of a ROSA26 promoter, leads to increased 
cell proliferation and activation of the PI3K and protein 
kinase B in heart and brain. No changes in apoptosis were 
reported [40]. Several reasons may have contributed to these 
discrepancies, including cell-type specific roles for Nestin 
as well as limitations in the technical strategies. However, it 
is interesting to hypothesize that presence of Nestin may be 
required for survival of the stem cell, whereas different lev-
els of Nestin may have an impact on its proliferative status. 
Future work will be required for a better understanding of 
the specific role of Nestin in asymmetric cell division and 
stem cell self-renewal.
Differentiation
As previously mentioned, asymmetric cell division and 
cytoskeletal rearrangements also imply a distinct morphol-
ogy for one of the daughter cells that is committed to differ-
entiation, and later the migration of mature cells, processes 
particularly evident during neurogenesis [41]. Cell differ-
entiation is connected to changes in cellular shape based on 
intermediate filament remodeling, with several of these pro-
teins co-expressed in a specific cell subset for a certain time 
during differentiation [17]. For instance, in the hematopoietic 
system, lamins determine the stem cell commitment to dif-
ferent cell lineages (Table 1). Lamins of type B predominate 
only in hematopoietic progenitors, erythroid differentiation is 
accompanied by high lamin A and low lamin B1 expression, 
and megakaryocytes do not develop under lamin suppression 
[42]. Nestin may be a good candidate to regulate differentia-
tion, as its expression is enriched in several subsets of stem 
cells and down-regulated in committed cells [2, 9]. Surpris-
ingly, to date studies are scarce and further, Nestin abolishment 
has no impact on neuronal differentiation during development 
in vivo [36]. Potentially, the massive cell death that occurs in 
the neural tube of Nestin−/− embryos may mask other sub-
tle yet relevant functions of Nestin. These would rather be 
evaluated using fine-tuned controlled levels of Nestin in time, 
like inducible mouse models. Yet during myogenesis, Nestin 
downregulation enhances differentiation, with no impact on 
proliferation of undifferentiated dividing myoblasts. In this 
system, Nestin prevents myoblast differentiation by inhibiting 
activation of cyclin-dependent kinase 5 through p25, crucial 
step in the process [43].
Migration
Intermediate filaments are also key players in polarity main-
tenance in migrating cells [44, 45]. Migration of hematopoi-
etic cell subsets through micropores is limited by the ratio of 
lamin A:B that also provides nuclear stiffness [42]. Vimentin 
has been extensively studied, and in wounded monolayers of 
retinal pigment epithelial cells, it interacts with microtubules 
to maintain cell polarization during healing [46]. Vimentin 
also regulates focal adhesion dynamics (Table 1). During 
development, Nestin deficiency does not influence neuronal 
movement or attachment of NSCs in vivo [36], but this func-
tion would be more adequately analyzed using fine-tuned 
inducible models.
Upon malignancy, growing body of evidence relates Nes-
tin to improved ability of cancer cells to migrate and metas-
tasize [15]. In prostate cancer cell lines, Nestin knockdown 
inhibits in vitro migration and invasion, with no effect on 
cell growth, and leads to a fivefold reduction of metastases 
compared to controls in spite of uncompromised tumori-
genicity at the inoculation site [47]. However, in the same 
system, others have found that Nestin downregulation leads 
to a significant increase in phosphorylated focal adhesion 
kinase and integrin-dependent matrix degradation, and 
thereby to subsequent cell invasion [48]. Thus, Nestin may 
have different effects on cell function depending on cell sub-
set, and transformation stage in case of malignancy.
In vivo models for the study of  Nestin+ cells 
and their progeny
The generation of transgenic models has allowed to visualize 
and isolate  Nestin+ cells through reporter genes, or to fol-
low the fate of  Nestin+ in vivo and genetically control their 
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numbers and expression of additional genes, using the cre 
recombinase technology under the Nestin promoter (Fig. 2). 
The interest focused initially on NSCs in developing and 
adult brains [2, 20], but extended in recent years to other 
subsets of stem cells like those of the mesenchymal line-
age [9]. Remarkably, in vivo models target selective, yet to 
2183Nestin-expressing progenitor cells: function, identity and therapeutic implications 
1 3
a certain extent overlapping,  Nestin+ cell subsets. Further, 
in spite of their high value, data derived from these tools 
should be considered in the context of their pitfalls as well. 
Hence, combination of models is preferred for complete 
answers to the questions under study.
Nestin−/−
The first and most cited Nestin−/− mouse model is embry-
onically lethal after E8.5 due to massive apoptosis of neural 
tube cells (Fig. 2a). This biological tool generated through 
targeting of the coding region of Nestin exon 1 by homolo-
gous recombination was essential to uncover the strong 
effect of Nestin on NSC survival and self-renewal [36], but 
it does not allow the study of additional functions of Nes-
tin or its relevance at later stages. Surprisingly, Park and 
colleagues found no obvious abnormalities in other organs 
where  Nestin+ cells are present, further supporting that Nes-
tin function is indeed complex and cell-specific. Later, a 
second Nestin−/− mouse model was generated by gene tar-
geting, where the regions deleted included most exon 1 and 
part of the 5´ upstream region [37]. This is a less acknowl-
edged Nestin−/− mouse model that is viable, and show 
grossly normal development of the central nervous system 
but impaired motor coordination. The latter was attributed to 
aberrant neuromuscular junction areas with increased num-
bers of acetylcholine receptor clusters, nerve length, and 
endplate bandwidth [37]. Surprisingly, at the anatomical 
level, the authors reported no apparent morphological abnor-
malities resulting from the absence of Nestin expression by 
histological studies of the central nervous system or mag-
netic resonance imaging. However, these examinations could 
not rule out the possibility of subtle functional changes aris-
ing from the absence of Nestin in NSCs. Unknown technical 
issues related to the genetic engineering may underlie these 
puzzling differences that deserve further investigation. These 
may include generation of unidentified genetic defects in the 
first Nestin−/− mouse model and/or emergence of a truncated 
protein with partial function in the second one. Further, in 
spite of the potential value of a conditional and/or inducible 
knockout mouse model for Nestin expression, Nestinfl/fl mice 
have not been generated to date.
Nestin‑gfp
Nestin gene expression is regulated by enhancer elements 
residing in the intronic regions, and although Nestin is 
expressed in a variety of tissues, these regulatory elements 
show some selectivity for cell subsets. During embryonic 
development, members of the POU (Pit-Oct-Unc) transcrip-
tion factor family bind to the Nestin neural enhancer at the 
second intron and establish neuroepithelial cell specificity 
[49]. By selection only of these regulatory elements of the 
second intron and the upstream flanking area, Mignone and 
colleagues [2] generated an essential reporter mouse model 
where they narrowed the spectrum of cells in which gfp is 
expressed and directed the fluorescence more specifically 
to NSCs (Fig. 2b). Later, low frequencies of Nestin-gfp+ 
have been reported in a variety of tissues, like bone marrow, 
where they represent mainly primitive perivascular mesen-
chymal stromal cells (MSCs) [9]. Interestingly, in fetal bone 
marrow, the majority of neural crest cells traced with Wnt1-
cre2 are Nestin-gfp+ cells that preserve MSC activity, but do 
not produce chondrocytes. Conversely, they help establish 
the hematopoietic stem cell (HSC) niche that supports HSC 
function. Neonatal Nestin-gfp+ cells also contain Schwann 
cell precursors that may be distinguished from MSCs by 
their absence of platelet-derived growth factor receptor α 
(Pdgfrα) [50]. Nevertheless, mature Schwann cells in the 
adult bone marrow do not seem to express Nestin-gfp [51].
The most remarkable limitation in this reporter line is 
represented by gfp turnover, which implies that fluorescence 
may be detected after Nestin expression is terminated. In sev-
eral tissues, like brain and bone marrow, several Nestin-gfp+ 
subsets have been identified according to gfp levels [2, 21]. 
Surprisingly, bone marrow Nestin-gfpbright cells were low for 
Fig. 2  In vivo models for the study of  Nestin+ cells and their prog-
eny. a Nestin−/− mouse model. Nestin−/− mice are embryonically 
lethal (E8.5) due to neural stem cell apoptosis, which uncovered the 
role of Nestin in neural stem cell self-renewal and survival [36]. This 
model does not allow fine-tuned control of Nestin expression in space 
and time, so an improved strategy would be use of conditional and/
or inducible knockout models, like Nestinfl/fl intercrossed with cre 
lines of interest. b Nestin-gfp reporter mouse model. Pit-Oct-Unc 
transcription factors bind to the Nestin neural enhancer at the second 
intron to establish neuroepithelial cells specificity. Nestin-gfp mouse 
model was generated by selection only of these regulatory elements 
of the second intron and upstream area [2] in an attempt to direct gfp 
expression to neural stem cells. Later, presence of Nestin-gfp+ cells 
has been described in other tissues, particularly bone marrow. Nes-
tin-gfpbright and Nestin-gfpdim cells have been reported with no robust 
evidence of differential and corresponding endogenous Nestin expres-
sion. In addition, gfp turnover may contribute to fluorescence inten-
sity levels, which represents another limitation that may be overcome 
by fluorescent protein fusion to Nestin. c Nestin-creERT2 lineage trac-
ing in vivo. This mouse model is based on cre technology, coupled 
to the modified estrogen ligand-binding domain (ERT2). The system 
activates under administration of tamoxifen, allowing tracing of Nes-
tin lineage in a temporal manner, both in embryonic and adult stages. 
However, tamoxifen has physiological effects that must be distin-
guished using controls lacking creERT2 and treated with tamoxifen. d 
Nestin-creERT2 iDTA mouse model for Nestin lineage depletion. This 
mouse model is used to reduce numbers of  Nestin+ cells and their lin-
eage upon tamoxifen administration. It is useful to study their con-
tribution to disease development. However, depletion of cells occurs 
through diphtheria toxin expression and subsequent necrosis, which 
implies release of cellular content and potential sterile inflammation. 
Nes Nestin, Gfp green fluorescent protein, POU Pit-Oct-Unc, Tam 
tamoxifen, NSC neural stem cells, NSPC neural stem and progenitor 
cells, MSC mesenchymal stromal cells, iDTA inducible diphtheria 
toxin A subunit
◂
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Nestin expression in samples analyzed by high throughput 
sequencing [21]. In addition, although  Gfap+ Schwann cells 
in the adult bone marrow do not express Nestin-gfp [51], 
both markers colocalize when Nestin is detected by antibody 
[52]. Limitations in gfp detection methods, Nestin antibodies 
and stromal cell obtaining protocols may contribute to these 
inconsistencies. Further, using distinct transgene constructs 
and/or control under different regulatory elements, other 
Nestin-gfp+ mouse models have been generated that differ 
in gfp patterns [53]. Thus, gfp expression may not totally 
reproduce endogenous Nestin expression.
Nestin‑cre/Nestin‑creERT2
Cre mediated recombination is a broadly used genetic tool 
to conditionally delete or express selected genes, and to line-
age trace progenitor populations during development when 
combined to a reporter gene with an upstream floxed-stop 
cassette [54]. Several Nestin-cre lines have been generated 
[55, 56], and used to direct recombination to neural stem 
and intermediate progenitor cells [57]. However, the rate of 
Nestin-cre driven recombination may reach sufficient levels 
in NSCs and progenitors only during late embryonic and 
early postnatal stages [58]. Further, in Nestin-cre models, 
recombination occurs in  Nestin+ cells and is maintained in 
their progeny. This allows lineage tracing of  Nestin+ cells 
but represents a drawback in studies restricted to  Nestin+ 
cells only, given that their progeny of differentiated cells 
cannot be ruled out. This may underlie controversial find-
ings like presence of recombination in fully differentiated 
neurons [59] or their poor colony forming unit fibroblastic 
activity in adult bone marrow [60].
In addition to central/peripheral nervous system and 
bone marrow, Nestin-cre is expressed in a variety of tissues 
including kidney, heart, lung, muscle, intestine, pancreas, 
spleen and skin. Besides, genomic insertion of cre may 
influence physiological function due to random integration 
that may disrupt endogenous gene expression and/or to ille-
gitimate recombination catalysis, among others. Potentially, 
this may explain the marked metabolic phenotype reported 
in Nestin-cre mice with no targeted gene. Thus, Nestin-cre 
controls are necessary in experimental designs to prevent 
misinterpretation of results [61].
Nestin-creERT2 is an improved genetic approach to control 
Nestin lineage in a temporal manner [62], which is particu-
larly relevant for studies on adult  Nestin+ cells (Fig. 2c). This 
transgenic mouse model expresses a fusion protein encoding 
cre coupled to the modified estrogen receptor ligand-binding 
domain (ERT2). CreERT2 is silent but activates upon estrogen 
analog tamoxifen administration. Duration of tamoxifen treat-
ment influences efficiency of recombination, which needs to 
be considered when interpreting data obtained with this 
model, as well as when making comparisons among studies. 
Administration of tamoxifen in neonatal Nestin-creERT2 mice 
promotes higher recombination efficiency than in adults [50]. 
In addition, tamoxifen has significant effects on cell function 
and physiology [63] that cannot be distinguished unless use of 
appropriate experimental controls lacking creERT2 and treated 
with tamoxifen. Further, potential interactions between tamox-
ifen and the selective genetic manipulation in Nestin cell line-
age may occur and render data interpretation more difficult.
iDTR/iDTA
Cre technology under the Nestin promoter allows deple-
tion of  Nestin+ cells in vivo, when intercrossed with the cre 
recombinase-inducible diphtheria toxin receptor line (iDTR) 
[64]. In adult Nestin-creERT2 iDTR mice, tamoxifen and 
diphtheria toxin treatment severely reduces the numbers of 
bone marrow  Nestin+ cells [9]. To date, however, it remains 
unclear whether both subsets of adult bone marrow  Nestin+ 
cells, Nestin-gfpbright and Nestin-gfpdim cells, are equally 
depleted by this strategy or to what extent. Further, ablation 
of  Nestin+ cells may occur in additional organs, like brain, 
which may have an indirect impact on hematopoiesis and 
complicate interpretation of results. Mouse cells are signifi-
cantly more resistant to diphtheria toxin than human cells, 
mainly due to three amino acid changes in DTR involved 
in binding of diphtheria B subunit [65]. However, some 
degree of toxicity from diphtheria toxin treatment cannot 
be discarded.
An improved approach is the cre recombinase-inducible 
diphtheria toxin mouse line (iDTA) that expresses the toxic 
diphtheria A subunit [66] (Fig. 2d). In adult Nestin-creERT2 
iDTA mice, treatment with tamoxifen does not affect mature 
bone marrow Schwann cells, but reduces the numbers of 
 Nestin+ MSCs [51]. The utility of this model is outstanding, 
but potential unspecific effects are not accurately defined. 
Diphtheria toxin causes necrosis by inactivation of elon-
gation factor 2 through adenosine di-phosphate ribosyla-
tion, thereby preventing protein synthesis. Minor leakage 
in expression may be detrimental given the high toxicity 
of DTA, efficient to arrest translation as a single molecule 
inside the cell [67]. Further, necrosis implies release of cel-
lular content. The iDTA system lacks the B subunit of the 
toxin responsible for binding to the receptor, so no detri-
mental effects are expected from DTA discharge. However, 
subsequent sterile inflammation at the site of cell death may 
occur and impact phenotypes under study.
Identity of  Nestin+ cells
The above transgenic models have helped identify different 
subsets of  Nestin+ cells, depending on factors like location 
and time (developmental or adult stage), among others. In 
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this section, we discuss the comprehensive literature on the 
main subsets of  Nestin+ cells characterized to date in two 
major locations, nervous system and bone marrow (Fig. 3).
Central and peripheral nervous systems
In the developing brain, the regulatory elements at the sec-
ond intron direct gfp expression in Nestin-gfp mice to the 
neuroepithelium of the embryo where Nestin is expressed 
[2, 5, 49]. In the adult brain, gfp is expressed widely in the 
areas where Nestin expression is found, like the lateral wall 
of the lateral ventricle, olfactory subependyma and dentate 
gyrus, characterized by persistent production of new neu-
rons, whereas it is absent both in differentiated cells and in 
areas containing fully differentiated cells. Nestin-gfp+ cells 
of the rostral migratory stream comprise two subsets accord-
ing to gfp intensity; gfpbright cells are positive for Gfap and 
gfpdim cells co-express III-tubulin. These two subsets were 
suggested to be progenitor cells at different stages of differ-
entiation, where gfpbright cells would be stem cells and gfpdim 
cells would represent more mature precursors [2]. Moreover, 
most of the proliferating cells are also gfp+. In the proximal 
part of the rostral migratory stream, the majority of  BrdU+ 
nuclei is found among gfpbright cells, whereas in distal areas, 
close to the olfactory bulb, most  BrdU+ cells have low levels 
of gfp. This further supports that gfp levels distinguish sub-
sets of neuronal progenitors in the adult brain [2]. However, 
Nestin expression was not confirmed in sorted gfpbright and 
gfpdim cells, and gfp levels may not exactly mirror expression 
of the endogenous Nestin gene.
As previously discussed, Nestin-gfp+ cells are enriched 
in neurosphere-forming cells, and actually most of the 
neurosphere-forming cells of the adult brain are contained 
within gfp+ cells. The neurospheres generated from indi-
vidual gfp+ cells contain a large number of gfpbright cells, 
with certain degree of heterogeneity in gfp levels. When 
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Bergmann glia cell 
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Fig. 3  Identity of  Nestin+ cells found in neural tissues and bone 
marrow. The main subsets of  Nestin+ cells present in neural-related 
tissues (brain, cerebellum, retina, gut, skin) and bone marrow are 
shown. These subsets comprise neural stem cells, neural progenitor 
cells, astrocytes, radial glia-like precursors, subsets of glia cells with 
regenerative potential, several types of neural precursor cells outside 
brain, pericytes, mesenchymal stromal cells, endothelial cells, and 
Schwann cell precursors. They are distinct in their location, func-
tional properties and co-expression of selective markers.  Nestin+ cells 
are represented in green. In brain and bone marrow, Nestin-gfpbright 
and gfpdim cells have been described according to gfp intensity lev-
els in Nestin-gfp mice. NSC neural stem cells, NPC neural progeni-
tor cell, MSC mesenchymal stromal cell, Gfap glial fibrillary acidic 
protein, SOX2 sex determining region Y-box 2, p75 NTR p75 neuro-
trophin receptor, NG2 neural/glial antigen 2, Leptin R leptin receptor
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the neurospheres are plated on laminin substrate, fluores-
cence declines dramatically and most cells express markers 
of differentiated cells like III-tubulin, Gfap, or 2′,3′-Cyclic-
nucleotide 3′-phosphodiesterase [2].
Interestingly, most  Nestin+ cells express Gfap, although 
co-expression is dependent on species and developmental 
stage. In primates, radial glia cells in the developing neo-
cortex express Gfap from the initiation of neurogenesis, 
in contrast to rodents where Gfap is expressed after birth 
[68–70]. In addition, both Nestin and Gfap are expressed 
in the subclass of radial glia-like precursors in the adult 
mouse dentate gyrus [71]. Both markers are present in Mul-
ler glia cells that differentiate to neural progenitor/stem cells 
to regenerate lost photoreceptors and neurons in the retina 
under pathological conditions [72], and in cerebellum Berg-
mann glia cells which express the transcription factor sex 
determining region Y-box 2 (Sox-2) [73]. Besides Gfap and 
Nestin, astrocytes and astrocytoma cells express vimentin 
and possibly synemin [74] in a dense filament network [45]. 
The integrity of this network is required for correct nuclear 
positioning, microtubule organization, and cell polarity [33, 
45]. Recently, another potential neurogenic cell subset has 
been identified in the adult cerebellar cortex that expresses 
Sox-2 and Nestin-gfp, and lacks markers of differentiation 
like Gfap and S100β [75].
In the periphery, a subset of  Nestin+ cells give rise to 
adult myenteric neurons in gut, suggesting that they are neu-
ral precursors cells [20]. Nestin-gfp+ cells form a network 
distributed through most of the wall of the small intestine. 
They are particularly abundant in the submucosal zone and 
muscular layers, but not present in the epithelial lining. This 
network is mainly perivascular, but small numbers of cells 
are also found in the myenteric plexus [20]. The potential 
neural crest origin of Nestin-gfp+ cells was traced with Wnt1-
cre together with a reporter, which labels Nestin-gfp+ cells in 
the myenteric plexus but not the perivascular compartment. 
Perivascular Nestin-gfp+ cells express the pericyte marker 
nerve/glial antigen 2 (NG2). Conversely, Nestin-gfp+ cells in 
the myenteric ganglia may express p75 Neurotrophin recep-
tor (p75Ntr), CD49b, Gfap and S100β, but do not express 
the neuronal marker protein gene product 9.5. Although lim-
ited, the neurosphere-forming capacity of myenteric cells 
is restricted to Nestin-gfp+ cells (~ 3.5%) and particularly 
to those that coexpress p75Ntr (~ 10%). Neurospheres dif-
ferentiate in vitro to neurons and glia, and cells traced with 
Nestin-creERT2 in vivo include both HuC/D+ neurons and 
S100β cells. Surprisingly, expression of the reporter in this 
mouse line correlates with endogenous Nestin expression 
in the plexus. Further, cells isolated by the reporter also 
form neurospheres that differentiate into neurons in vitro, 
and engraft and differentiate to HuC/D+ neurons in vivo 
upon transplantation into the wall of recipient mice. Sox10-
H2BVenus mice and immunostaining with Nestin antibody 
was used to rule out the potential glial nature of Nestin-gfp+ 
[20]. However, as previously discussed, these two methods 
may detect only partially overlapping cell subsets.
In skin, a subset of adult stem cells, namely skin-derived 
precursors, was identified under culture adapted from gen-
eration of NSCs from brain [76]. This small subset of skin 
cells from adult mice form spheres, which dissociated and 
plated onto poly-d-lysine/laminin express Nestin in vitro. 
Skin-derived precursors can differentiate in vitro into neu-
rons, glia, smooth muscle cells and adipocytes. Unlike 
NSCs, skin-derived precursors express fibronectin. Further, 
skin-derived precursors do not express p75Ntr nor polysialic 
acid-neural cell adhesion molecule, and they did not dif-
ferentiate into tyrosine  hydroxylase+ neurons. Similar cells 
were found in adult human skin [76]. More recently, skin-
derived precursors showed differentiation in vitro into tyros-
ine hydroxylase and dopamine-β-hydroxylase neurons [77]. 
Single spheres generated from the skin of neonatal mice 
expressing yellow-fluorescent protein (Yfp) from the actin 
promoter transplanted into the chick neural crest migratory 
stream in ovo showed migration into peripheral neural crest 
targets and dermis.  Nestin+ cells are found in mouse skin, 
and neural crest derived cells traced with Wnt1-cre in vivo 
are present in the dermal papilla of the hair follicle [77]. 
However, the correspondence between both cell subsets was 
not confirmed. Further, the potential overlap between skin-
derived precursors and MSCs remains unclear. Later, Nestin-
gfp+ cells were observed in the hair follicle bulge [7]. They 
behave as stem cells, giving rise to much of the hair follicle 
during hair growth like the outer root sheath and the interfol-
licular vascular network. Nestin-gfp+ cells are negative for 
keratin 15 and are capable of differentiation into neurons, 
glia, keratinocytes, smooth muscle cells and melanocytes 
in vitro. Further, Nestin-gfp+ cells may give rise to neurons 
after in vivo transplantation to the subcutis of nude mice [7]. 
In humans,  Nestin+ cells that can be propagated and exhibit 
multipotent potential in vitro are also found in other loca-
tions, like eccrine and apocrine sweat glands of axillary skin 
[78], but it is unknown where they originate from.
Bone marrow
Adult HSCs have the capacity to both self-renew and dif-
ferentiate into all blood cell lineages, being responsible for 
blood production during the entire life [79]. The HSC niche 
is a dynamic entity that supports the function, fate and num-
bers of HSCs in the bone marrow where these cells reside 
[80]. MSCs are relevant components of the HSC niche, yet 
the absence of selective markers to track them in vivo has 
limited our understanding of their nature [81]. Further, limi-
tations in genetic tools for the study of MSCs have contrib-
uted to discrepancies among studies [82].
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In this scenario, Nestin-gfp+ cells in adult bone marrow 
were initially identified as MSCs that contain all the bone 
marrow colony forming unit fibroblastic activity and expand 
as mesenspheres that self-renew in serial transplantations. 
Nestin-gfp+ cells were described as perivascular cells closely 
associated to HSCs and sympathetic fibers, and enriched in 
expression of HSC maintenance genes. In this study, no gfp+ 
cells were found within the endothelial  CD31+ fraction in 
the bone marrow by microscopy or flow cytometry. Ex vivo, 
Nestin-gfp+ cells differentiate into osteoblastic, adipocytic 
and chondrocytic lineages, cells who do not express Nestin. 
In vivo, using Nestin-creERT2 intercrossed with a reporter 
line, gfp+ osteoblasts, osteocytes and chondrocytes were 
traced after 8 months chase with tamoxifen. In vivo deple-
tion of  Nestin+ cells and their progeny using Nestin-creERT2 
iDTR mice reduced HSCs numbers by four-fold, 1 month 
after administration of tamoxifen and diphtheria toxin [9].
Later, using whole-mount confocal immunofluorescence 
and computational modelling, two distinct Nestin-gfp+ cell 
subsets were identified according to fluorescence intensity 
by microscopy, Nestin-gfpbright cells are rare and found 
exclusively along arterioles and Nestin-gfpdim cells are retic-
ular in shape and associated with sinusoids. Nestin-gfpbright 
cells are enriched in colony forming unit fibroblastic activity 
and in the expression of HSC maintenance genes. Further, 
dormant HSCs localize close to Nestin-gfpbright cells and this 
protects them against genotoxic insults [21]. However, HSC 
maintenance and colony forming unit fibroblastic activity 
were traditionally related to perisinusoidal cells [83, 84]. 
Moreover, leptin receptor (Lepr)+ perisinusoidal cells traced 
cells using a constitutive cre system showed that these cells 
are an important source of stem cell factor, critically sup-
port HSC maintenance and partially overlap with Nestin-
gfp+ cells [85]. Nestin-gfpdim cells were indeed confirmed to 
largely overlap (~ 80%) with Lepr-cre cells, whereas Nestin-
gfpbright cells represent a distinct cell subset that is positive 
for the pericyte marker NG2 and α-smooth muscle actin. 
Using NG2-creERTM induced by tamoxifen together with a 
reporter mouse line intercrossed with Nestin-gfp mice, 30% 
of Nestin-gfpbright cells were labeled with the reporter but no 
labelling was found within Nestin-gfpdim cells. Depletion of 
 NG2+ cells in NG2-creERTM iDTR mice reduced Nestin-gfp-
bright and the HSC pool [21]. However, conditional deletion 
of stem cell factor or Cxcl12 in NG2-creERTM traced cells 
has no influence of the HSC pool [86], although a longer 
tamoxifen administration protocol to improve the efficiency 
of Cxcl12 deletion led to a significant reduction of the 
 CD150+  CD48− HSC pool [87]. In contrast, NG2-cre cells 
stain for Lepr and label both Nestin-gfp subsets, osteocytes, 
chondrocytes, adipocytes and a small fraction of endothe-
lial cells (~ 10%) [87]. Whereas deletion of Cxcl12 in Lepr-
cre targeted cells leads to mobilization of HSCs [88], the 
same strategy in NG2-cre cells leads to both mobilization 
and quiescence exit [87]. Moreover, NG2-cre but not NG2-
creERTM targeted cells seem to be a relevant source of stem 
cell factor [87]. This may be explained on the basis of their 
large overlap with  Lepr+ perivascular cells and maybe 
endothelial cells, both of which demonstrated as the major 
sources of stem cell factor in the bone marrow [85]. Hence, 
the nature of bone marrow mesenchymal Nestin-gfp+ cells, 
and in particular Nestin-gfpbright cells, remains controversial. 
These studies highlight the complexity of in vivo models 
and emphasize the importance of thorough consideration of 
experimental conditions for adequate data interpretation in 
the context of the bone marrow niche.
Using a milder enzymatic protocol that allows better 
preservation of antigen expression, Nestin-gfp+  CD31+ 
endothelial cells are detected in the fetal bone marrow, 
and their number increase with age [50]. This fact points 
out another major source of discrepancies among stud-
ies derived from different enzymatic digestion protocols, 
required for obtaining the stromal fraction of the bone mar-
row. Recently, the group of Lapidot described the existence 
of Nestin-gfp+ cells within the adult non-hematopoietic 
 (CD45−) endothelial  (CD31+) bone marrow fraction, and 
particularly restricted to Sca-1+  CD31high arterial bone 
marrow endothelial cells. Interestingly, bright Nestin-gfp+ 
Sca-1− MSCs are adjacent to Nestin-gfp+ Sca-1+ endothelial 
cells, and Nestin-gfp+  NG2+ MSCs are closely associated to 
Nestin-gfp+  NG2− blood vessels [10]. However, the potential 
lineage relationship between Nestin-gfp+ MSCs and Nes-
tin-gfp+ endothelial cells in the adult bone marrow remains 
unknown. In the embryonic perichondrium, Nestin-gfp+ 
comprise endothelial and non-endothelial cell subsets that 
interact with each other and increase their numbers during 
vascular invasion and endochondral ossification. Further, in 
the developing bone marrow, cells traced with Nestin-creERT2 
in vivo are predominantly endothelial cells, but encompass 
osteoblasts, osteocytes, stromal cells and chondrocytes 
as well [11]. Of note, different layers of endothelial and 
perivascular Nestin-gfp+ cells may make arterioles appear 
brighter under the microscope, which raises the possibil-
ity that arteriolar Nestin-gfpbright cells under the microscope 
may not completely overlap with the brightest cells isolated 
by FACS as single cells [50]. Moreover, fluorescence inten-
sity thresholds may not be fully comparable between both 
methods.
In fetal bone marrow, most neural crest cells traced with 
Wnt1-cre2 are Nestin-gfp+ cells that preserve MSC activ-
ity, but do not produce chondrocytes. Conversely, they sup-
port HSC function. Neonatal Nestin-gfp+ cells also contain 
 Gfap+ Schwann cell precursors that differ from Nestin-gfp+ 
MSCs in lack of Pdgfrα [50]. By immunohistochemical and 
ArrayScan analyses of the adult bone marrow, non-myeli-
nating Schwann cells positive for Gfap were found positive 
for Nestin and negative for Pdgfrα, all through antibodies. 
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Further, Pdgfrα+ MSCs and  Nestin+ cells largely over-
lap but show different distributions [52].  Gfap+ Schwann 
cells are in close association to arteries, but unfortunately 
colocalization of gfp and Gfap in Nestin-gfp mice was not 
confirmed [10]. Further, Nestin-gfpbright cells are in direct 
contact with  Gfap+ Schwann cells, but both markers were 
not reported to colocalize [21]. Hence, the relation between 
Schwann cells and Nestin-gfp+ cells in adult bone marrow 
is yet to be elucidated. Interestingly, using an in vivo model 
of hematopoietic malignancies, namely myeloproliferative 
neoplasms, we showed that both cell types are reduced in 
the disease bone marrow which contributes to pathogen-
esis. Nestin-gfp+ cells from disease mice are reduced in 
the expression of MSC and HSC niche-related genes, but 
enriched in Schwann cell genes and neural-related functional 
categories. Principal component analyses of genomic data 
confirmed that Nestin-gfp+ cells from disease mice cluster 
away from primitive MSCs and close to Schwann cells. 
However,  Gfap+ Schwann cells in the bone marrow do not 
seem to express gfp in Nestin-gfp mice, although both cells 
subsets are closely associated spatially. Additionally, selec-
tive depletion of  Nestin+ in vivo using Nestin-creERT2 iDTA 
mice did not affect Schwann cells but reduced numbers of 
 CD90+ mesenchymal cells [51]. Previously discussed factors 
related to the in vivo tools, like gfp patterns and efficiency 
of recombination, may have contributed to these intriguing 
results that should be subject of future research.
Role of  Nestin+ cells in pathogenesis 
and value of its targeting in therapeutic 
strategies
Recent body of evidence on Nestin and its role in tissue 
remodeling and cell regulation of other cell subsets, and 
particularly stem cells, suggests that Nestin may have great 
potential as target to develop new therapeutic strategies in 
the clinic and/or tools with diagnostic/prognostic value in 
patients.
Nervous system
Underlying the greatest challenge in finding cures for neu-
rodegenerative diseases there are several causes, including 
not fully understood driving forces and disease onsets far 
long prior to the stage of detectable symptoms. As previ-
ously discussed, compiled evidence supports Nestin as a 
good marker of NSCs and progenitors, so efforts are cur-
rently being directed to study its contribution in mecha-
nisms of disease and its targeting for development of novel 
therapeutic strategies and/or diagnostic/prognostic methods 
in diseases of the nervous system, particularly those with 
degenerative component.
Alzheimer’s disease is characterized by progressive depo-
sition of β-amyloid peptides in a variety of brain regions, 
and concomitant neuronal and synaptic loss as well as defec-
tive neurogenesis [89]. Presence of the ε 4 allele in apoli-
poprotein E (ApoE) represents the most important genetic 
risk factor for disease development [90]. Surprisingly, to 
date few molecules are described to play regulatory roles 
in adult neurogenesis with relevance to Alzheimer’s disease 
[91]. Using an ApoE-deficient mouse model intercrossed 
to Nestin-gfp mice, lack of ApoE increased proliferation 
of early NSCs and progenitors within the dentate gyrus, 
resulting in eventual depletion of the overall early progeni-
tor pool that coexpresses Nestin and Gfap [92]. Recently, 
mouse NSCs were isolated on the first day of birth, cul-
tured in vitro with retinoids acid to induce differentiation, 
and transplanted bilaterally at the hippocampus of amyloid 
precursor protein and presenilin-1 transgenic mice [93]. 
Although scarce information is provided on the nature of the 
stem cells used for therapy, fractions of cells were reported 
to express differentiation markers in vivo, including Gfap or 
microtubule-associated protein 2. This strategy restores the 
reduced numbers of  Nestin+ cells and promotes prolifera-
tion in dentate gyrus and subgranular zone, and increases 
numbers of synapses in the transplanted regions. The authors 
propose that resulting neurogenesis may be monitored by 
proton magnetic resonance spectroscopy in vivo, which in 
turn would be proportional to  Nestin+ cell improvements 
[93]. Future work should elucidate the value of  Nestin+ cells 
as potential therapeutic target and/or prognostic parameter 
with improved methods in patients of Alzheimer’s disease.
Hence, efforts are dedicated to improve the molecular 
imaging of Nestin in real time in vivo. Recently, a trans-
genic mouse model was generated bearing both luciferase 
and gfp under control of the Nestin promoter. This system 
allows to trace Nestin transcription in living animals using 
both bioluminescence and fluorescence, and a high resolu-
tion camera [94]. Interestingly, upon middle cerebral artery 
occlusion and lipopolysaccharide-induced innate immune 
system activation as models of stroke and neuroinflamma-
tion, respectively, Nestin expression patterns seem to shift 
from progenitors towards activated microglia/macrophages 
and astrocytes. Direct functional consequences of this shift 
are yet to be characterized but these data suggest that Nes-
tin may serve as biomarker of inflammatory responses in 
brain [94]. Indeed, development of improved non-invasive 
imaging tools for Nestin follow-up in patients will be highly 
relevant in the clinic.
Amyotrophic lateral sclerosis results from progressive 
motor neuron degeneration leading to impaired motility. 
The most frequent genetic cause is a hexanucleotide repeat 
expansion (GGG GCC ) (over hundreds) in a noncoding 
region of C9ORF72, protein found in neurons and presyn-
aptic terminals suspected to participate in protein trafficking. 
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This mutation is also common in familial frontotemporal 
degeneration, a related but different neurodegenerative 
disease [95]. Both gain- and loss-of-function mechanisms 
have been proposed. Recently, C9orf72 loss-of-function in 
 Nestin+ cells and their lineage was tested by intercrossing 
of C9orf72fl/fl and Nestin-cre mouse lines [96]. Although 
this is a broad strategy that involves absence of C9orf72 in 
neural progenitors, neurons and glial cells from develop-
mental stage, it is interesting to see that resulting mice lack 
hallmarks of amyotrophic lateral sclerosis, like reduction 
of motor neurons, astro- and microgliosis, and ubiquitina-
tion enhancement [96]. Hence, these data may have impli-
cations for development of therapies, as they may indicate 
that strategies targeting the repeat expansion that also reduce 
C9ORF72 expression are unlikely to have negative second-
ary effects due to the latter.
Parkinson’s disease is the result of massive degeneration 
of dopamine neurons in the midbrain, and particularly the 
substantia nigra, which causes motor symptoms like rest-
ing tremor, and other symptoms including neuropsychiatric 
[97]. Further, dopamine modulates neurogenesis that is then 
impaired in Parkinson’s disease patients [98]. Nestin-creERT2 
intercrossed with reporter mouse lines have been used to 
study the neurogenic capacity of  Nestin+ cells in midbrain 
under steady state conditions. Interestingly, Nestin-creERT2 
-traced cells are in low frequencies and show mature neu-
ronal phenotypes even after short-term tamoxifen treatments, 
but their function and gene expression differ from neigh-
boring cells that do not express the reporter [99]. Further, 
time-course analyses did not reveal classical neurogenesis 
evidenced by place of birth, neuronal differentiation, matura-
tion and integration, raising the possibility that some mature 
neurons may express Nestin in midbrain [99]. Others have 
found hints of differentiation by means of cell growth and 
higher levels of expression of mature neuronal genes over 
long periods, albeit low proliferative rate and no evidence 
of migration [100]. Interestingly, single-cell gene expression 
data suggested that up-regulation of mature neuronal genes 
in Nestin-creERT2 -traced midbrain cells occurs over several 
months, not days, providing robust evidence for presence 
of  Nestin+ neural progenitors in adult midbrain. However, 
controversial findings were described in a model of Parkin-
son’s disease induced by dopaminergic neuron degenera-
tion driven by 6-hydroxy-dopamine intra-cerebral injection. 
Here, numbers of Nestin-creERT2 -traced cells increase by 
two-fold in substantia nigra, with no changes in the expres-
sion on neuronal nuclear antigen. Remarkably, 4 days after 
tamoxifen many Nestin-creERT2 -traced cells have mature 
neuronal morphology, and are positive for both neuronal 
nuclear antigen and the pluripotency marker Sox-2. This 
short timeframe may be not enough for  Nestin+ progenitors 
to become mature neurons, again raising the possibility that 
mature neurons express Nestin and other immature genes 
under certain conditions and in contexts that may be not 
neurogenic [100]. Other authors have selectively deleted 
tyrosine hydroxylase in Nestin- or Sox-2-traced cells using 
creERT2 systems. 6 months after the start of a 6 week treat-
ment with tamoxifen, mice with Nestin-mediated tyrosine 
hydroxylase deletion showed lower numbers of tyrosine 
 hydroxylase+ neurons in substantia nigra, while no reduction 
was observed following Sox-2-mediated excision. This find-
ing further supports that Nestin-expressing cells regenerate 
dopaminergic neurons [101]. Previously discussed factors 
related to limitations of in vivo models may have influenced 
these controversial results that deserve further investigation 
and are highly relevant in search for therapeutic targets in 
Parkinson’s disease.
Cell therapy is an approach extensively pursued experi-
mentally due to its valuable therapeutic potential against 
neurodegenerative diseases like Parkinson. Endogenous 
NSCs and progenitors are unable to promote full and long-
lasting recovery [102]. Further, the source of cells is a heavy 
milestone. A potential strategy to overcome this limitation is 
generation of induced dopaminergic neurons from induced 
pluripotent stem cells derived from patients with Parkin-
son. As of today, however, induced dopaminergic neurons 
differ remarkably from primary midbrain neurons in global 
gene expression, particularly in genes related to matura-
tion [103]. Others have been able to elicit dopaminergic 
neuronal conversion from adult fibroblasts derived from 
healthy donors and Parkinson patients [104]. Numbers of 
resulting cells seem to be the weakness in this design. An 
exciting approach is the reprogramming from somatic cells 
into multipotent NSCs, which offers reduced risk of tumor 
formation versus induced pluripotent stem cells, and produc-
tion of higher amounts of homogeneous cell populations as 
compared to induced neuronal cells. Recently, induced NSCs 
were reprogrammed from mouse and human fibroblasts with 
introduction of the gene Sox-2 only [105]. Indeed, resulting 
cells express Nestin, and resemble NSCs in their morphol-
ogy, self-renewal, differentiation potential into mature neu-
rons, astrocytes and oligodendrocytes in vitro and in vivo, 
and gene expression profiles [105]. Others have found that 
Sox-2 alone shows limited conversion ability from adult 
human somatic cells [106]. In this work, let-7 microRNA 
was found critical for formation of paired box 6/NESTIN-
positive colonies to immunocytochemically characterize the 
NSCs induced from human adult fibroblasts, and for their 
proliferation and self-renewal [106]. Certainly, fine-tuned 
control of Nestin expression is a key and challenging factor 
that will provide a significant step forward towards genera-
tion of safe and functional induced NSCs suitable for patient 
therapy.
Scientific endeavor in search for alternative sources of 
NSCs and progenitors has led to consideration of bone mar-
row mesenchymal cells, with varying degree of success. 
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These cells are currently being tested in exploratory clinical 
trials against multiple sclerosis (i.e., NCT01854957), major 
cause of neurological disability with fast progression and 
young adult onset [107]. Immune cells targeting self-anti-
gens in the central nervous system in genetically susceptible 
individuals are thought to play a key role in loss of myelin 
and myelinating cells and subsequent damage to axons and 
neurons, but its true etiology remains elusive [108]. Upon 
intravenous injection, bone marrow stromal cells success-
fully infiltrate brain and spinal cord, and migrate towards 
lesions in multiple sclerosis. The beneficial effects of these 
cells are not fully understood but may include immunosup-
pression, neuroprotection, and/or differentiation, among oth-
ers [107]. Our recent work has evidenced that bone marrow 
 Nestin+ MSCs, with specialized HSC niche function, share 
a common neural crest ontology with neural progenitor cells 
[50]. In neonates, this fraction of specialized MSCs also 
contains Schwann cell precursors that can be differentiated 
into Schwann cells ex vivo [50, 51]. In adults,  Nestin+ MSCs 
and NSCs retain a number of similarities like expression 
of functional core markers, including Nestin, and ex vivo 
self-renewal ability as measured by sphere formation. Fur-
ther, MSCs activate the Schwann cell program in vivo as a 
consequence of the neuroglial damage caused in the bone 
marrow by mutated HSCs [51]. Hence, it is reasonable to 
hypothesize that bone marrow  Nestin+ MSCs may provide a 
useful source for cell therapy in neurodegenerative diseases. 
Future work is required to validate this hypothesis.
Bone marrow
Given the role of  Nestin+ cells within the healthy HSC niche, 
contributing to HSC maintenance in the bone marrow and 
mediating HSC circadian mobilization into the periphery 
[9, 21, 87, 109],  Nestin+ cells have recently gained interest 
in the context of bone marrow pathologies, and particularly 
hematological malignancies.
In preclinical models of myeloproliferative neoplasms, 
a subclass of hematological cancer, our recent work has 
provided evidence on the pathogenic role of bone marrow 
 Nestin+ cell alterations, and the promising therapeutic value 
of their targeting [51]. The acquired somatic mutation in the 
Janus kinase 2 (JAK2) gene resulting in a valine to phenyla-
lanine substitution at position 617 (JAK2-V617F) is present 
in the majority of these patients, and renders hematopoietic 
precursors with proliferative and survival advantages [110]. 
Using a transgenic mouse model that expresses the human 
mutant JAK2-V617F under the endogenous promoter of 
Jak2 in an inducible manner, we showed that interleukin-1β 
produced at early disease stage, at least partially by mutant 
HSCs, induces damage of neuroglial fibers. Reduced sym-
pathetic regulation together with interleukin-1β stimula-
tion results in Nestin-gfp+ cell apoptosis that then allows 
expansion of mutant HSCs.  Nestin+ cell number and Nestin 
messenger RNA expression are also reduced in the bone 
marrow of patients with myeloproliferative neoplasms. The 
pathogenic role of Nestin-gfp+ cell reduction was uncovered 
by enforced reduction of these cells using Nestin-creERT2 
iDTA mice, which aggravates hallmarks of disease, includ-
ing hematological parameters and osteosclerosis of the 
bone marrow. As previously discussed, selective depletion 
of  Nestin+ in vivo using Nestin-creERT2 iDTA mice did not 
affect Schwann cells but reduced numbers of  CD90+ mesen-
chymal cells. Besides, selective deletion of Cxcl12 in Nestin-
creERT2 mice leads to expansion of the HSC compartment, 
suggesting the contribution of Cxcl12 in control of mutant 
hematopoietic progenitor numbers. However, potential tar-
geting of  Nestin+  CD31+ endothelial cells cannot be ruled 
out with these Nestin-creERT2 strategies and may have con-
tributed to the observed phenotypes. Conversely, compensa-
tion of sympathetic regulation on  Nestin+ cells using beta-3 
adrenergic agonist treatment rescues numbers of Nestin-
gfp+ and Schwann cells, blocks Schwann cell gene program 
activation in Nestin-gfp+ cells, improves levels of Cxcl12, 
ameliorates hallmarks of disease and interleukin-1β levels, 
and efficiently decreases mutant hematopoietic progeni-
tors with no effect on normal progenitors. Although beta-3 
adrenergic receptors are somewhat restricted to selective 
cell subsets and they are not present in hematopoietic cells, 
certain types of adipocytes and endothelial cells may show 
expression in addition to  Nestin+ cells [111]. Nonetheless, 
our data suggest that targeting the beta-3 adrenergic receptor 
with agonist drugs may have clinical implications to improve 
treatment of patients with myeloproliferative neoplasms, and 
 Nestin+ cells contribute to these events [51]. Further, the 
most important hematopoietic disease-related pain affects to 
bone, and it was traditionally related to osteolytic lesions and 
infiltration of bone marrow with malignant cells. Our work 
may provide hints linking pathogenesis and pain in hemat-
opoietic malignancies through neuroglial damage, in both 
disease mice and humans, which may contribute to bone 
pain reported in patients [112]. Sympathetic nervous system 
compensation with beta-3 adrenergic agonists did not rescue 
neural fibers in mouse models [51], so it will be interesting 
to see their ability to relieve pain in patients.
In an MLL-AF9+ acute myeloid leukemia model, gener-
ated after transduction of  Linage−c-Kit+Sca-1+ cells with 
the MLL-AF9 oncogene and serial transplantation of these 
cells, neuropathy promotes leukemic bone marrow infil-
tration [113]. In their model, development of acute mye-
loid leukemia disrupts neural fibers and the quiescence of 
 Nestin+ cells, leading to their expansion by 3.8-fold with 
osteoblastic priming ex vivo. Transplantation of leukemic 
cells using recipients Osterix-creERT2 together with the 
reporter tdTomato to label osteolineage cells showed, under 
continuous tamoxifen administration via diet, increased bone 
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remodeling with accumulation of osteoblasts and reduc-
tion of mature bone-forming osteoblasts [113]. Osterix is 
expressed earlier than osteocalcin in the osteoblast lineage 
[114], but still osterix-expressing cells do not represent a 
pool of progenitors with self-renewal capacity in healthy 
adult mice [115]. Osterix-labeled cells from leukemic mar-
row expressed Lepr, unlike mature osteoblast from healthy 
mice, but participation of  Nestin+ cells in these processes 
was only inferred and not confirmed in vivo.  NG2+ periarte-
riolar cells are reduced in  acute myeloid leukemia, and this 
is not likely due to increased differentiation, as no double 
positive cells for Pdgfrα and CD51 were fate mapped by 
NG2-creERTM with a reporter [113]. Nevertheless, contribu-
tion of NG2 traced cells to more differentiated osteoblasts 
was not studied. Further, reduction of  NG2+ cells and their 
expression of HSC-supportive genes was only correlated and 
not causally related to lower numbers of long-term HSCs. 
Similarly, the reduced expression of HSC maintenance and 
retention genes in  Nestin+ cells was only correlated and not 
causally related to mobilization of progenitors to circula-
tion and spleen. Nevertheless, the beta-2 adrenergic receptor 
expressed on stromal cells seems to play a role in acute mye-
loid leukemia development as higher leukemic bone marrow 
infiltration occurs in mice lacking this receptor. Conversely, 
administration of the beta-2 adrenergic agonist Clenbuterol 
hydrochloride led to reductions of phenotypic leukemic stem 
cells in bone marrow, spleen, and blood and tended to extend 
survival. However, Clenbuterol also had a cell-autonomous 
action in vitro, enhancing proliferation of MLL-AF9 cells 
[113], which discourages its use as a potential therapeutic 
target. Future work should address the causal contribution 
of  Nestin+ cells in acute myeloid leukemia development, 
and its potential use as target for novel drug development.
Conclusions
A large body of evidence points to Nestin as a unique inter-
mediate filament that accompanies self-renewal capacity in 
several subsets of stem cells and progenitors, particularly 
those of the neural and mesenchymal lineages. Nestin seems 
to have an impact on stem cell migration and differentiation, 
yet the knowledge on the underlying mechanisms is limited. 
Surprisingly, little is also known on the regulatory signaling 
pathways that control Nestin expression and function, which 
should be the focus of future work. The precise identity of 
 Nestin+ cells is currently the target of extensive endeavor in 
in vivo models. Data obtained from these tools are highly 
valuable, but it should be considered in the context of their 
weaknesses as well to prevent misinterpretation. In paral-
lel, the mechanistic role and promising therapeutic value 
of  Nestin+ cells is also under research in preclinical models 
of disease, especially neurodegenerative diseases and bone 
marrow malignancies. Future improved in vivo models 
and detection tools will help characterize the real nature 
of  Nestin+ cells and confirm their application as therapy in 
those diseases.
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